Evolutional depression model in the time of pandemic. Psychocherapy and psychopharmacotherapy alliance

The article presents epidemiological study data on depressive disorders prevalence and dynamic of the population emotional well-being and affective disorders incidence in the world during the COVID 19 pandemic. Typical anxiety-depressive states are described with the emphasis on the specific COVID 19 stress syndrome. The article highlights the depression evolutional model as an adaptation mode to the unfavorable defined environmental conditions with the limited life-supporting resources, the nowadays pandemic situation can be definitely considered as one of them. The research data uniting psychodynamic and biological approach are considered in particular genetic specific of the serotoninergic regulation and environmental influence of the early adverse experience vulnerability with the later depressive disorders manifestation Additionally the research results on the bidirectional relationships between affective and immunological disturbances with the immune-metabolic syndrome description are presented. The peculiarities of the depression patients cognitive functioning are identified with specific personal negative rigid cognitive style and executive cognitive functions consideration. The combined therapy algorithm including implementation of SSRI antidepressants and cognitive-behavior psychotherapy, cognitive remediation programs is proposed.

1. Alexandrovsky YA, Chekhonin VP. Clinical-immunological research in borderline mental disorders. Vestnik rossiiskoi akademii medicinskih nauk.1999; 7:12-15. (In Russ.).

2. Alexandrovsky YA, Chekhonin VP. Klinicheskaya immunologia pogranichnih psychicheskih rasstroistv. M. Geotar-med. 2005. (In Russ.).

3. Bekker RA, Bykov YV. Fluvoxamine: a broad spectrum antidepressant with several distinctive niches for its clinical use (a literature review). Psihiatriya i psihofarmakoterapiy. 2019; 1:11–26 (In Russ.).

4. Vasileva AV. Pandemic and mental adjustment disorders. Therapy options. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2020; 120(5):146-152. https://doi.org/10.17116/jnevro2020120051146

5. Vasileva AV, Karavaeva TA, Poltorak SV, Kolesova YP. Neurotic level anxiety disorders (panic, generalized anxiety and anxiety-phobic disorders) psychopharmacoceutical treatment principles and algorithms. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. 2016; 1:3-9. (In Russ.).

6. Vasileva A.V. First WHO Infodemiology Conference: multidiscipline Cooperation in Tackling Misinformation during COVID-19 Pandemic. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. 2020; 3:93-95. https://doi.org/10.31363/2313-7053-2020-3-93-95 18. (In Russ.).

7. Garanyan NG. Depression and personality: international research review, part II. Socialnaya I klinicheskaya psychiatria. 2009; 3:80-92 (In Russ.).

8. Giljarovskij V.A. Psihiatrija. M: Medgiz, 1954; 520. (In Russ.).

9. Dubnitskaya EB. Experience of using fluvoxamine (fevarin) in psychogenic depression. Psihiatriya i psihofarmakoterapiya. 2005; 2: 77–78 (In Russ.).

10. Ivanov MV. Fluvoxamine: Opportunities in drug therapy psychiatric disorders. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. 2012;4:91-96 (In Russ.).

11. Neznanov NG, Kibitov AO, Rukavishnikov GV, Mazo GЕ. The prognosticrole of depression as a predictor of chronic somatic diseases manifestation. Terapevticheskij arhiv. 2018; 90(12):122-132. (In Russ.).

12. Neznanov NG, Mazo GЕ, Rukavishnikov GV. Antidepressants impact on the depression patients cognitive functioning. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. 2015; 3:75-82. (In Russ.).

13. Neznanov NG, Mazo GE., Rukavishnikov GV, Kibitov AO. Depression as a predictor of somatic disorders: pathological premises and genetic risks. Uspehi fiziologicheskih nauk. 2017; 48(4):29-39. (In Russ.).

14. Oleichik IV, Shishkovskaia TI, Baranov PA. Contemporary approaches to correction of cognitive impairment in endogenous depression. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. 2020; 4:82-93. https://doi.org/10.31363/2313-7053-2020-4-82-93(In Russ.).

15. Palin AV, Afyan MV, Kozlov MY, Slyusarev AS. Features of cognitive remediation in patients with affective disorders. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019; 119(9):118-122. (In Russ.). https://doi.org/10.17116/jnevro2019119091118 (In Russ.).

16. Sorokin MYu, Kasyanov ED, Rukavishnikov GV, Makarevich OV, Neznanov NG, Lutova NB, Mazo GE. Psychological reactions of the population as a factor of adaptation to the COVID-19 pandemic. Obozrenie psihiatriii medicinskoj psihologii imeni V.M. Behtereva. 2020; 2:87-94. (In Russ.). https://doi.org/10.31363/2313-7053-2020-2-87-94 (In Russ.).

17. Smulevich AB, Ilyina NA, Chitlova VV. Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label Uncontrolled and Randomized Multicenter Observational Study. Psihiatriya i psihofarmakoterapiya. 2016; 1:4–10 (In Russ.).

18. Syunyakov TS. Effects of fluvoxamine on the melatonin levels: literature overview and possible clinical implication. Psihiatriya i psihofarmakoterapiya. 2014; 1:33–8 (In Russ.).

19. Холмогорова А.Б., Пуговкина О.Д. Основные этапы и направления изучения когнитивных дисфункций при депрессиях. Медицинская психология в России: электрон. науч. журн. 2015; 6(35) [http://mprj.ru]. mprj.ru; 2015 [процитировано 10 марта 2021]. Доступно: http://mprj.ru/archiv_global/2015_6_35/nomer02.php

20. Chitlova VV. Anxious depressions: aspects of psychopathology and therapy. Psihiatriya i psihofarmakoterapiya. 2012; 4:27–33 (In Russ.).

21. Andrews PW, Bharwani A, Lee KR, Fox M, Thomson JA Jr. Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neurosci Biobehav Rev. 2015; 51:164-88. doi:10.1016/j.neubiorev.2015.01.018.

22. Ashton AK, Jamerson BD, L Weinstein W, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Curr Ther Res Clin Exp. 2005; 66(2):96106. doi:10.1016/j.curtheres.2005.04.006

23. Asmundson GJG, Taylor S. Coronaphobia: fear and the 2019-nCoV outbreak. J Anxiety Disord. 2020;70. [https://pubmed.gov]. pubmed; 2020 [процитировано 10 марта 2021]. Доступно: https://pubmed.ncbi.nlm.nih.gov/32078967/

24. Beck AT, Bredemeier K. A Unified Model of Depression: Integrating Clinical, Cognitive, Biological, and Evolutionary Perspectives. Clinical Psychological Science. 2016; 4(4):596-619. doi:10.1177/2167702616628523

25. Brummelte S, Mc Glanaghy E, Bonnin A, Oberlander TF. Developmental changes in serotonin signal-ing: Implications for early brain function, behavior and adaptation. Neuroscience. 2017; 342:212-231. doi: 10.1016/j.neuroscience.2016.02.037.

26. Bueno-Notivol J, Gracia-García P, Olaya B, Lasheras I, López-Antón R, Santabárbara J. Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies. Int J Clin Health Psychol. 2021; 21(1):100196. doi: 10.1016/j.ijchp.2020.07.007. Epub 2020 Aug 31. PMID: 32904715; PMCID: PMC7458054.

27. Chang O, Huang E, Zuo QK. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2021; 1486(1):90-111. doi: 10.1111/nyas.14506. Epub 2020 Oct 2. PMID: 33009668; PMCID: PMC7675607.

28. Chekroud AM, Gueorguieva R, Krumholz HM et al. Reevaluating the efficacy and predictability of antidepressant treatments. A symptom clustering ap-proach. JAMA Psychiatry 2017; 74:370-8. 12. Boschloo L, Bekhuis E, Weitz ES et al. The symptom-specific efficacy of an-tidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data metaanalysis. World Psychiatry 2019; 18:183-91

29. Chekroud AM, Zotti RJ, Shehzad Z et al. Crosstrial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 2016; 3:243-50

30. Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, Saxena S. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016; 3(5):415-24. doi: 10.1016/S2215-0366(16)30024-4.

31. Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, Saxena S. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016; 3(5):415-24. doi: 10.1016/S22150366(16)30024-4

32. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128):1357-1366. doi: 10.1016/S01406736(17)32802-7.

33. Connor TJ, Kelliher P, Shen Y, Harkin A, Kelly JP, Leonard BE. Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol Biochem Behav. 2000; 65:591-597.https://doi.org/10.1016/s0091-3057(99)00192-6

34. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008; 9(1):46-56. doi: 10.1038/nrn2297.

35. Disner SG, Beevers CG, Haigh EA, Beck AT. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011; 12(8):467-77. doi: 10.1038/nrn3027.

36. Disner, S., Beevers, C., Haigh, E. et al. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011; 12:467–477. https://doi.org/10.1038/nrn3027 EPA recommendations on COVID-19. [https://www.europsy.net/]. europsy; 2020 [процитировано 10 марта 2021]. Доступно: https://www.europsy.net/covid-19-resource-centre

37. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, Whiteford HA. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013; 43(3):471-481. doi: 10.1017/S0033291712001511

38. Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T, Whiteford HA. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS One. 2013; 8(7):e69637. doi: 10.1371/journal.pone.0069637. PMID: 23922765; PMCID: PMC3726670

39. Fried EI, Epskamp S, Nesse RM et al. What are «good» depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. J Affect Disord 2016; 189:314-20

40. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ. 2018; 361:k1951. Published 2018 May 23. doi:10.1136/bmj.k1951

41. Hao Y, Hu Y, Wang H, Paudel D, Xu Y, Zhang B. al. The Effect Of Fluvoxamine On Sleep Architecture of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study. Nature and Science of Sleep. 2019; 11:291–300.

42. Iniesta R, Malki K, Maier W et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res. 2016; 78:94-102.

43. Investing in treatment for depression and anxiety leads to fourfold return. [http://europsy.net]. Europsy; [accessed 18.03.2021] Available: https://www.who.int/ru/news/item/13-04-2016-investing- in-treatment-for-depression-and-anxiety-leads-tofourfold-return

44. Key facts. Depression [https://www.who.int]. Who; [accessed 10.03.2021]. Available:https://www.who.int/news-room/fact-sheets/detail/depression

45. Lamers F, Milaneschi Y, Vinkers CH, Schoevers RA, Giltay EJ, Penninx BWJH. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain Behav Immun. 2020; 88:174-183. doi: 10.1016/j.bbi.2020.04.002.

46. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(22):2292-2300. doi: 10.1001/jama.2020.22760.

47. Maj, M., Stein, D.J., Parker, G., Zimmerman, M., Fava, G.A., De Hert, M., Demyttenaere, K., McIntyre, R.S., Widiger, T. and Wittchen, H.‐U. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020; 19:269-293. https://doi.org/10.1002/wps.20771

48. Malhi G.S., Parker G.B., Gladstone G. et al. Recognizing the anxious face of depression. Journal of Nervous and Mental Disorders. 2002; 190.:366–373

49. McGinty EE, Presskreischer R, Han H, Barry CL. Psychological distress and loneliness reported by US adults in 2018 and April 2020. JAMA. 2020; published online June 3. https://doi.org.10.1001/jama.2020-9740

50. Milaneschi Y, Lamers F, Berk M, Penninx BWJH. Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. Biol Psychiatry. 2020; 88(5):369-380. doi: 10.1016/j.biopsych.2020.01.014.

51. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009; 65(9):732-41. doi: 10.1016/j.biopsych.2008.11.029.

52. Nouwen A, Adriaanse MC, van Dam K, Iversen MM, Viechtbauer W, Peyrot M, Caramlau I, Kokoszka A, Kanc K, de Groot M, Nefs G, Pouwer F; European Depression in Diabetes (EDID) Research Consortium. Longitudinal associations between depression and diabetes complications: a systematic review and meta-analysis. Diabet Med. 2019; 36(12):1562-1572. doi: 10.1111/dme.14054.

53. Ottevanger EA. The efficacy of fluvoxamine in patients with severe depression. British J Clinical Research 1991; 2: 125-32

54. Pierce, M., Hope, H., Ford, T., Hatch, S., Hotopf, M., John, A., Kontopantelis, E., et al. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population.. The lancet. Psychiatry. 2020; 7(10):883-892.

55. Rajkumar RP. COVID-19 and mental health: A review of the existing literature. Asian J Psychiatr. 2020; 52:102066. doi: 10.1016/j.ajp.2020.102066.

56. Reynolds C. Optimizing personalized management of depression: the importance of real-world contexts and the need for a new convergence paradigm in mental health. World Psychiatry. 2020; 19(3):266268.

57. Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, Gaultier A. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019; 6:11(478):eaau5266. doi: 10.1126/scitranslmed.aau5266.

58. Seftel D, Boulware DR. Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19. Open Forum Infect Dis. 2021; 8(2):ofab050. doi: 10.1093/ofid/ofab050. PMID: 33623808; PMCID: PMC7888564.

59. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010; 71(10):1259-1272. doi: 10.4088/JCP.09r05346blu.

60. Sonawalla SB, Spillmann MK, Kolsky AR et al. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry. 1999; 60(9):580–583.

61. Taylor S, Landry CA, Paluszek MM, Fergus TA, McKay D, Asmundson GJG. COVID stress syndrome: Concept, structure, and correlates. Depress Anxiety. 2020; 37(8):706-714. doi:10.1002/da.23071

62. Weissman M., Markowitz J., Klerman G. Clinician’s Guide to Interpersonal Psychotherapy. 2007; Oxford UP.

63. WHO Coping with stress during the 2019-nCoV outbreak. [https://www.who.int]. Who; [Accessed on 17 April, 2020]. Available: https://www.who.int/docs/default-source/coronaviruse/coping-withstress.pdf